Literature DB >> 2306220

Inhibition and inactivation of NADH-cytochrome c reductase activity of bovine heart submitochondrial particles by the iron(III)-adriamycin complex.

B B Hasinoff1.   

Abstract

The NADH-cytochrome c reductase activity of bovine heart submitochondrial particles was found to be slowly (half-time of 16 min) and progressively lost upon incubation with the Fe2(+)-adriamycin complex. In addition to this slow progressive inactivation seen on incubation, a reversible fast phase of inhibition was also seen. However, if EDTA was added to the incubation mixture within 15 s, the slow progressive loss in activity was largely preventable. Separate experiments indicated that EDTA removed about one-half of the iron from the Fe2(+)-adriamycin complex in about 40 s. These results indicated the requirement for iron for the inactivation process. Since the Vmax. for the fast phase of inhibition was decreased by the inhibitor, the inhibition pattern was similar to that seen for uncompetitive or mixed-type inhibition. The direct binding of both Fe3(+)-adriamycin and adriamycin to submitochondrial particles was also demonstrated, with the Fe3(+)-adriamycin complex binding 8 times more strongly than adriamycin. Thus binding of Fe3(+)-adriamycin to the enzyme or to the inner mitochondrial membrane with subsequent generation of oxy radicals in situ is a possible mechanism for the Fe3(+)-adriamycin-induced inactivation of respiratory enzyme activity.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2306220      PMCID: PMC1133711          DOI: 10.1042/bj2650865

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  29 in total

1.  Differences in O2 reduction by the iron complexes of adriamycin and daunomycin: the importance of the sidechain hydroxyl group.

Authors:  J L Zweier; L Gianni; J Muindi; C E Myers
Journal:  Biochim Biophys Acta       Date:  1986

2.  Mechanism of inhibition of mitochondrial enzymatic complex I-III by adriamycin derivatives.

Authors:  E Goormaghtigh; P Huart; R Brasseur; J M Ruysschaert
Journal:  Biochim Biophys Acta       Date:  1986-09-25

3.  Binding of transferrin-iron by adriamycin at acidic pH.

Authors:  E J Demant; N Nørskov-Lauritsen
Journal:  FEBS Lett       Date:  1986-02-17       Impact factor: 4.124

4.  Release of iron from ferritin by cardiotoxic anthracycline antibiotics.

Authors:  C E Thomas; S D Aust
Journal:  Arch Biochem Biophys       Date:  1986-08-01       Impact factor: 4.013

5.  Adriamycin and its iron(III) and copper(II) complexes. Glutathione-induced dissociation; cytochrome c oxidase inactivation and protection; binding to cardiolipin.

Authors:  B B Hasinoff; J P Davey
Journal:  Biochem Pharmacol       Date:  1988-10-01       Impact factor: 5.858

6.  The Adriamycin (doxorubicin)-induced inactivation of cytochrome c oxidase depends on the presence of iron or copper.

Authors:  B B Hasinoff; J P Davey; P J O'Brien
Journal:  Xenobiotica       Date:  1989-02       Impact factor: 1.908

7.  The interaction of the cardioprotective agent ICRF-187 [+)-1,2-bis(3,5-dioxopiperazinyl-1-yL)propane); its hydrolysis product (ICRF-198); and other chelating agents with the Fe(III) and Cu(II) complexes of adriamycin.

Authors:  B B Hasinoff
Journal:  Agents Actions       Date:  1989-03

8.  Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer.

Authors:  J L Speyer; M D Green; E Kramer; M Rey; J Sanger; C Ward; N Dubin; V Ferrans; P Stecy; A Zeleniuch-Jacquotte
Journal:  N Engl J Med       Date:  1988-09-22       Impact factor: 91.245

9.  The iron(III)-adriamycin complex inhibits cytochrome c oxidase before its inactivation.

Authors:  B B Hasinoff; J P Davey
Journal:  Biochem J       Date:  1988-03-15       Impact factor: 3.857

10.  Redox cycling of anthracyclines by cardiac mitochondria. I. Anthracycline radical formation by NADH dehydrogenase.

Authors:  K J Davies; J H Doroshow
Journal:  J Biol Chem       Date:  1986-03-05       Impact factor: 5.157

View more
  4 in total

Review 1.  Doxorubicin-Induced Cardiomyopathy in Children.

Authors:  Trevi R Mancilla; Brian Iskra; Gregory J Aune
Journal:  Compr Physiol       Date:  2019-06-12       Impact factor: 9.090

2.  The one-ring open hydrolysis product intermediates of the cardioprotective agent ICRF-187 (dexrazoxane) displace iron from iron-anthracycline complexes.

Authors:  J L Buss; B B Hasinoff
Journal:  Agents Actions       Date:  1993-09

3.  The removal of metal ions from transferrin, ferritin and ceruloplasmin by the cardioprotective agent ICRF-187 [(+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane] and its hydrolysis product ADR-925.

Authors:  B B Hasinoff; S V Kala
Journal:  Agents Actions       Date:  1993-05

4.  Dexrazoxane prevents doxorubicin-induced long-term cardiotoxicity and protects myocardial mitochondria from genetic and functional lesions in rats.

Authors:  D Lebrecht; A Geist; U-P Ketelsen; J Haberstroh; B Setzer; U A Walker
Journal:  Br J Pharmacol       Date:  2007-05-21       Impact factor: 8.739

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.